Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Metabolic profiling reveals that PNPLA3 induces widespread effects on metabolism beyond triacylglycerol remodeling in Huh-7 hepatoma cells.

Min HK, Sookoian S, Pirola CJ, Cheng J, Mirshahi F, Sanyal AJ.

Am J Physiol Gastrointest Liver Physiol. 2014 Jul 1;307(1):G66-76. doi: 10.1152/ajpgi.00335.2013. Epub 2014 Apr 24.

2.

PNPLA3, the triacylglycerol synthesis/hydrolysis/storage dilemma, and nonalcoholic fatty liver disease.

Sookoian S, Pirola CJ.

World J Gastroenterol. 2012 Nov 14;18(42):6018-26. doi: 10.3748/wjg.v18.i42.6018.

3.

Expression and characterization of a PNPLA3 protein isoform (I148M) associated with nonalcoholic fatty liver disease.

Huang Y, Cohen JC, Hobbs HH.

J Biol Chem. 2011 Oct 28;286(43):37085-93. doi: 10.1074/jbc.M111.290114. Epub 2011 Aug 30.

4.

Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis.

Smagris E, BasuRay S, Li J, Huang Y, Lai KM, Gromada J, Cohen JC, Hobbs HH.

Hepatology. 2015 Jan;61(1):108-18. doi: 10.1002/hep.27242. Epub 2014 Oct 1.

5.

PNPLA3 mediates hepatocyte triacylglycerol remodeling.

Ruhanen H, Perttilä J, Hölttä-Vuori M, Zhou Y, Yki-Järvinen H, Ikonen E, Käkelä R, Olkkonen VM.

J Lipid Res. 2014 Apr;55(4):739-46. doi: 10.1194/jlr.M046607. Epub 2014 Feb 7.

6.

PNPLA3 I148M polymorphism, clinical presentation, and survival in patients with hepatocellular carcinoma.

Valenti L, Motta BM, Soardo G, Iavarone M, Donati B, Sangiovanni A, Carnelutti A, Dongiovanni P, Rametta R, Bertelli C, Facchetti F, Colombo M, Fargion S, Fracanzani AL.

PLoS One. 2013 Oct 14;8(10):e75982. doi: 10.1371/journal.pone.0075982. eCollection 2013.

7.

A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis.

He S, McPhaul C, Li JZ, Garuti R, Kinch L, Grishin NV, Cohen JC, Hobbs HH.

J Biol Chem. 2010 Feb 26;285(9):6706-15. doi: 10.1074/jbc.M109.064501. Epub 2009 Dec 23.

8.

PNPLA3 is regulated by glucose in human hepatocytes, and its I148M mutant slows down triglyceride hydrolysis.

Perttilä J, Huaman-Samanez C, Caron S, Tanhuanpää K, Staels B, Yki-Järvinen H, Olkkonen VM.

Am J Physiol Endocrinol Metab. 2012 May 15;302(9):E1063-9. doi: 10.1152/ajpendo.00125.2011. Epub 2012 Feb 14.

9.

Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis.

Li JZ, Huang Y, Karaman R, Ivanova PT, Brown HA, Roddy T, Castro-Perez J, Cohen JC, Hobbs HH.

J Clin Invest. 2012 Nov;122(11):4130-44.

10.

PNPLA3 I148M variant in nonalcoholic fatty liver disease: demographic and ethnic characteristics and the role of the variant in nonalcoholic fatty liver fibrosis.

Chen LZ, Xin YN, Geng N, Jiang M, Zhang DD, Xuan SY.

World J Gastroenterol. 2015 Jan 21;21(3):794-802. doi: 10.3748/wjg.v21.i3.794. Review.

11.

PNPLA3 rs738409C/G polymorphism in cirrhosis: relationship with the aetiology of liver disease and hepatocellular carcinoma occurrence.

Falleti E, Fabris C, Cmet S, Cussigh A, Bitetto D, Fontanini E, Fornasiere E, Bignulin S, Fumolo E, Bignulin E, Pirisi M, Toniutto P.

Liver Int. 2011 Sep;31(8):1137-43. doi: 10.1111/j.1478-3231.2011.02534.x. Epub 2011 Apr 19.

PMID:
21745286
12.

PNPLA3 I148M variant and hepatocellular carcinoma: a common genetic variant for a rare disease.

Valenti L, Dongiovanni P, Ginanni Corradini S, Burza MA, Romeo S.

Dig Liver Dis. 2013 Aug;45(8):619-24. doi: 10.1016/j.dld.2012.12.006. Epub 2013 Jan 16. Review.

13.

Hepatic steatosis and PNPLA3 I148M variant are associated with serum Fetuin-A independently of insulin resistance.

Rametta R, Ruscica M, Dongiovanni P, Macchi C, Fracanzani AL, Steffani L, Fargion S, Magni P, Valenti L.

Eur J Clin Invest. 2014 Jul;44(7):627-33. doi: 10.1111/eci.12280.

PMID:
24828988
14.

PNPLA3/adiponutrin functions in lipid droplet formation.

Chamoun Z, Vacca F, Parton RG, Gruenberg J.

Biol Cell. 2013 May;105(5):219-33. doi: 10.1111/boc.201200036. Epub 2013 Apr 17.

PMID:
23398201
15.

PNPLA3 I148M polymorphism and progressive liver disease.

Dongiovanni P, Donati B, Fares R, Lombardi R, Mancina RM, Romeo S, Valenti L.

World J Gastroenterol. 2013 Nov 7;19(41):6969-78. doi: 10.3748/wjg.v19.i41.6969. Review.

16.

PNPLA3 variant I148M is associated with altered hepatic lipid composition in humans.

Peter A, Kovarova M, Nadalin S, Cermak T, Königsrainer A, Machicao F, Stefan N, Häring HU, Schleicher E.

Diabetologia. 2014 Oct;57(10):2103-7. doi: 10.1007/s00125-014-3310-0. Epub 2014 Jun 29.

PMID:
24972532
17.

A feed-forward loop amplifies nutritional regulation of PNPLA3.

Huang Y, He S, Li JZ, Seo YK, Osborne TF, Cohen JC, Hobbs HH.

Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7892-7. doi: 10.1073/pnas.1003585107. Epub 2010 Apr 12.

18.

Circulating triacylglycerol signatures in nonalcoholic fatty liver disease associated with the I148M variant in PNPLA3 and with obesity.

Hyysalo J, Gopalacharyulu P, Bian H, Hyötyläinen T, Leivonen M, Jaser N, Juuti A, Honka MJ, Nuutila P, Olkkonen VM, Oresic M, Yki-Järvinen H.

Diabetes. 2014 Jan;63(1):312-22. doi: 10.2337/db13-0774. Epub 2013 Sep 5.

19.

PNPLA3 Ile148Met variant and hepatocellular carcinoma: a matter of fat.

Valenti L.

Dig Liver Dis. 2012 Dec;44(12):974-5. doi: 10.1016/j.dld.2012.08.023. Epub 2012 Sep 24. No abstract available.

PMID:
23010516
20.

PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells.

Pirazzi C, Valenti L, Motta BM, Pingitore P, Hedfalk K, Mancina RM, Burza MA, Indiveri C, Ferro Y, Montalcini T, Maglio C, Dongiovanni P, Fargion S, Rametta R, Pujia A, Andersson L, Ghosal S, Levin M, Wiklund O, Iacovino M, Borén J, Romeo S.

Hum Mol Genet. 2014 Aug 1;23(15):4077-85. doi: 10.1093/hmg/ddu121. Epub 2014 Mar 25.

Supplemental Content

Support Center